Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-AMTG
- Development stage
- Unknown
- Lead developer
- Technical University of Munich
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-AMTG (also known as [68Ga]Ga-AMTG) is a gallium-68 labeled gastrin-releasing peptide receptor (GRPR) antagonist developed for positron emission tomography (PET) imaging of GRPR-expressing malignancies, such as prostate cancer and breast cancer. It is a structurally modified derivative of the GRPR antagonist RM2, where the metabolically unstable L-tryptophan at position 8 is substituted with α-methyl-L-tryptophan (α-Me-L-Trp8). This modification significantly enhances the peptide's resistance to enzymatic degradation in vivo, resulting in improved metabolic stability and higher tumor-to-background ratios compared to its parent compound. 68Ga-AMTG is utilized as a diagnostic imaging agent in theranostic applications, often paired with therapeutic counterparts like 177Lu-AMTG or 161Tb-AMTG.
- Other names
- 68Ga-alpha-Me-L-Trp8-RM268Ga-α-Me-Trp8-RM2[68Ga]Ga-AMTG[68Ga]Ga-alpha-Me-L-Trp8-RM2gallium (68Ga) AMTGgallium Ga 68 AMTG
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on 68Ga-AMTG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-AMTG.